{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ODD",
  "name": "ODDITY Tech Ltd.",
  "url": "https://orbyd.app/dossiers/ODD/",
  "json_url": "https://orbyd.app/dossiers/ODD.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Growth-compounder narrative is dead: Q1 first orders -50%, revenue -26%, and the $9.25→~$17.88 summer bounce has bled back to $14.12. The Q2 print slipped from mid-August to 2026-09-09, leaving a month with no dated catalyst and price still above every post-Q1 Street target but Evercore's $15.",
  "invalidation_trigger": "A weekly close below $13 abandons the post-crash shelf and re-opens the $9.25 area; secondary condition: the 2026-09-09 Q2 print shows first orders still down more than 40% YoY with CPA unimproved, or the FY2026 positive-adjusted-EBITDA guide is withdrawn.",
  "catalyst_date": "2026-09-09",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "consumer-discretionary-rotation",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer (Israel): reports via 6-K/20-F, not 10-Q — quarterly detail is thinner than a US domestic filer's.",
    "Dual-class structure: listed Class A versus founder-held Class B super-voting shares; public holders do not control the vote.",
    "Reporting cadence slipped twice in 2026 — Q1 on 2026-06-02 versus a prior early-May pattern, Q2 to 2026-09-09 versus 2025-08-04 for Q2 2025.",
    "Buyback authorization had $167.3M remaining as of the Q1 2026 report; the issuer is an active bidder in its own Class A stock.",
    "The 'largest advertising partner' behind the CPA blowout has never been named by the company, so the claim cannot be cross-checked externally."
  ],
  "body_markdown": "## Current Thesis\nThe compounder narrative that carried ODDITY to a 52-week high of $63.68 is finished, and the replacement narrative — normalization of the IL MAKIAGE paid-acquisition engine — has no dated evidence behind it until **2026-09-09**. Since the last note the two things that changed both cut against the recovery camp: price gave back the bounce (a 2026-07-03 close near $17.88 to **$14.12 on 2026-08-07**, roughly -21%), and the Q2 print was pushed to September 9 (announced 2026-07-22), five weeks later than the 2025-08-04 date used for Q2 2025. That leaves a month of no company-dated event with the stock still trading above every published post-Q1 target except Evercore's $15. Over three months the name is nearly flat (-4.5%) having travelled from roughly $14.8 down to $9.25 and back up to $17.88 — churn, not a base. RSI(14) at 38.3 is neither washed out nor trending.\n\n## Bull Case\n- **Q1 2026 (2026-06-02): revenue $197.9M, -26% YoY** — inside the pre-announced ~-30% cut, the single datapoint the normalization camp anchors on.\n- **Repeat orders -15% against first orders -50% (Q1 disclosure).** The installed base held; management frames the shortfall as an advertising-partner auction dislocation rather than demand erosion.\n- **Balance sheet is not the problem: $667.4M in cash, equivalents and investments plus $350M undrawn credit at Q1 2026.** A market cap in the mid-hundreds of millions against that stack limits solvency risk.\n- **The issuer is a buyer.** Q1 2026: ~6.1M Class A shares repurchased for $82.3M, with $167.3M of authorization left. Separately, on 2026-06-12 the company retired $50M face of 0% exchangeable notes due 2030 for $35M — roughly 70 cents on the dollar, ~$15M accretive, and it shrinks the 2030 dilution overhang.\n- **FY2026 guide still calls for positive adjusted EBITDA** despite a Q1 adjusted EBITDA of -$7.0M, which implies management expects an H2 swing.\n- **Prior-cycle economics were real:** FY2025 adjusted EBITDA of $163M with Q4 2025 revenue +24% YoY (reported February 2026). The model produced cash before the acquisition channel jammed.\n- **Product pipeline is dated:** Methodiq launched 2025-11-18; a fourth brand has been slated for 2026.\n\n## Bear Case\n- **Q2 2026 was guided down 25–30% YoY at the Q1 report.** The September 9 print is not scheduled to show growth; the debate is only over the shape of the decline.\n- **Gross margin fell to 69.7% in Q1 2026 from 74.9% a year earlier,** with a $21.4M net loss. Margin, the core of the long case, went with the cohorts.\n- **First orders -50% is a cohort hole that feeds forward.** DTC repeat revenue is a function of prior new-customer cohorts, so a lost H1 2026 acquisition year pressures 2027 repeat revenue even if CPA normalizes tomorrow.\n- **Price sits above the Street.** Post-Q1 targets: Barclays $8, Morgan Stanley $10, Jefferies $10.25, Truist $12, Evercore ISI $15; Goldman moved to Sell and KeyBanc to Sector Weight. Consensus target was cut from $17.33 to $10.09. At $14.12 the tape is still discounting a recovery the analyst community has not yet underwritten.\n- **The reporting calendar has slipped twice this year** — Q1 landed 2026-06-02 against a historical early-May cadence, and Q2 moved to 2026-09-09 against 2025-08-04 for the prior-year quarter. The company has not tied the change to any disclosed problem; the observable is the slip itself.\n- **Single-partner dependency.** The company has not named the advertising partner, so the CPA claim cannot be cross-checked against a third party's disclosures.\n\n## Setup & Price Structure\n**Life-cycle: DEAD.** The dating is explicit: guidance suspension and the CPA disclosure in February 2026; the 2026-06-02 Q1 print with revenue -26% and first orders -50%; a drawdown to -77.8% from the $63.68 52-week high; and the failure of the summer bounce, which topped near $17.88 on 2026-07-03 and closed at $14.12 on 2026-08-07. Structure is broken in the sense the label describes — there is no base, no rising trend to hold, and the recovery attempt has already surrendered most of its gain. A turnaround narrative may eventually be written here, but nothing dated supports relabelling it before September 9.\n\nCrowding and positioning observables, stated without a verdict:\n- Distance from the 52-week high is -77.8% (basis 2026-08-07), and the 2026 low near $9.25 is about 35% below the last close — the downside reference is closer than the upside one.\n- RSI(14) 38.3: no oversold capitulation reading, no momentum.\n- The last close is above four of five published post-Q1 price targets ($8/$10/$10.25/$12) and below only Evercore's $15.\n- Supply is being absorbed by the issuer, not sold by it: $82.3M of Q1 repurchases, $167.3M authorization remaining, and a discounted convert retirement on 2026-06-12. No insider selling or equity issuance into the bounce has been disclosed in the period covered here.\n- The next binary is 31 days out, so the near-term tape has no scheduled information event to price against.\n\n## Catalyst Calendar (next 30 days)\n- **No company-dated event between 2026-08-09 and 2026-09-08.** The window is empty; the bounce and fade have both happened on flow rather than disclosure.\n- **2026-09-09 (confirmed, announced 2026-07-22): Q2 2026 results, before US market open, call at 8:30 a.m. ET.** One day outside the 30-day window and the only thing that resolves anything: first-order trend, CPA direction, whether Q2 landed inside the -25% to -30% guide, and whether the FY2026 positive-adjusted-EBITDA guide survives.\n- **~2026-11 (est.): Q3 2026 results.** The second read, and the one that tests whether H1 cohort damage shows up in repeat revenue.\n\n## What Would Change Our Mind\nThe structure that has to hold is the post-crash shelf built between the $9.25 low and the July bounce; losing it re-opens the low. Concretely, a **weekly close below $13** abandons that shelf and marks the recovery attempt as a failed bounce rather than a base. The fundamental condition that would break the recovery case independently: a Q2 print on 2026-09-09 showing first orders still down more than 40% YoY with no CPA improvement, or withdrawal of the FY2026 positive-adjusted-EBITDA guide.\n\nWhat would force an upgrade instead: first orders inflecting to better than -20% YoY with gross margin recovering back toward the 74.9% of Q1 2025, Q2 revenue landing above the -25% end of the guide, and price reclaiming the $17.88 area on volume. Absent one of those, the September 9 print is a gap-risk event with a two-sided distribution and no informational edge available before it.\n\n## Correlation Notes\n- **Performance-marketing-dependent DTC cohort.** The read-across runs to names whose unit economics live and die on paid-social CPA. Any disclosure from a large advertising platform about auction or algorithm changes is a direct input to ODDITY's cost line; the company has not named its partner, so this is an inference, not a confirmed linkage.\n- **Beauty comparables** (e.l.f. Beauty, Coty and the broader mass-prestige complex) drive sentiment on category demand, but ODDITY's problem is channel-specific — its 2026 drawdown has been idiosyncratic rather than a sector move.\n- **Small-cap consumer discretionary beta.** With a broken chart and a thin institutional target band, the name will amplify risk-off moves in the small-cap consumer complex more than it participates in rallies.\n- **Israel-domiciled foreign private issuer.** Reporting cadence, filing format and disclosure granularity follow 20-F/6-K conventions rather than US quarterly practice, which is part of why the calendar has moved twice this year.",
  "first_seen": "2026-07-12",
  "last_analyzed": "2026-08-09T18:54:33+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}